Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Alkyllithiums and aryllithiums may also react with N,N-disubstituted amides to give aldehydes and ketones, and symmetrical ketones by reacting with carbon monoxide. They thermally decompose to eliminate a β-hydrogen, producing alkenes and lithium hydride: another route is the reaction of ethers with alkyl- and aryllithiums that act as strong bases. In non-polar solvents, aryllithiums react as the carbanions they effectively are, turning carbon dioxide to aromatic carboxylic acids (ArCO2H) and aryl ketones to tertiary carbinols (Ar'2C(Ar)OH). Finally, they may be used to synthesise other organometallic compounds through metal-halogen exchange.
Djenkolic acid (or sometimes jengkolic acid) is an naturally occurring organic compound with the formula CH2(SCH2CH(NH2)CO2H)2. It is sulfur-containing nonproteinogenic amino acid found in the djenkol beans of the Southeast Asian plant Archidendron jiringa. Its chemical structure is similar to cystine but contains a methylene (single carbon) unit between the two sulfur atoms. Dry djenkol beans contain about 20 grams of djenkolic acid per kilogram. It has also been reported in smaller amounts in the seeds of other leguminous plants such as Leucaena esculenta (2.2 g/kg) and Pithecolobium ondulatum (2.8 g/kg).
Slow oxidative (type I) fibers contract relatively slowly and use aerobic respiration to produce ATP. Fast oxidative (type IIA) fibers have fast contractions and primarily use aerobic respiration, but because they may switch to anaerobic respiration (glycolysis), can fatigue more quickly than slow oxidative fibers. Fast glycolytic (type IIX) fibers have fast contractions and primarily use anaerobic glycolysis. The FG fibers fatigue more quickly than the others. Most skeletal muscles in a human contain all three types in varying proportions.
Sources: en.wikipedia.org
== Benign neoplasms (210–229) == 210 Benign neoplasm of lip, oral cavity, and pharynx 211 Benign neoplasm of other parts of digestive system 211.3 Colon Familial adenomatous polyposis 212 Benign neoplasm of respiratory and intrathoracic organs 212.0 Nasal cavities middle ear and accessory sinuses 212.1 Larynx 212.2 Trachea 212.3 Bronchus and lung 212.4 Pleura 212.5 Mediastinum 212.6 Thymus 212.7 Heart Myxoma Rhabdomyoma 213 Benign neoplasm of bone and articular cartilage 213.9 Bone and articular cartilage, site unspecified Chondroma 214 Lipoma 215 Other benign neoplasm of connective and other soft tissue 216 Benign neoplasm of skin Melanocytic nevus 217 Benign neoplasm of breast 218 Uterine leiomyoma 219 Other benign neoplasm of uterus 220 Benign neoplasm of ovary 221 Benign neoplasm of other female genital organs 222 Benign neoplasm of male genital organs 223 Benign neoplasm of kidney and other urinary organs 224 Benign neoplasm of eye 225 Benign neoplasm of brain and other parts of nervous system 226 Benign neoplasm of thyroid glands 227 Benign neoplasm of other endocrine glands and related structures 228 Hemangioma and lymphangioma, any site 228.0 Hemangioma, any site 228.1 Lymphangioma, any site 229 Benign neoplasm of other and unspecified sites
: equilibrium In order to meet the thermodynamic condition for equilibrium, the Gibbs energy must be stationary, meaning that the derivative of G with respect to the extent of reaction, ξ, must be zero. It can be shown that in this case, the sum of chemical potentials times the stoichiometric coefficients of the products is equal to the sum of those corresponding to the reactants. Therefore, the sum of the Gibbs energies of the reactants must be the equal to the sum of the Gibbs energies of the products.
The social organization of the earliest Paleolithic (Lower Paleolithic) societies remains largely unknown to scientists, though Lower Paleolithic hominins such as Homo habilis and Homo erectus are likely to have had more complex social structures than chimpanzee societies. Late Oldowan/Early Acheulean humans such as Homo ergaster/Homo erectus may have been the first people to invent central campsites or home bases and incorporate them into their foraging and hunting strategies like contemporary hunter-gatherers, possibly as early as 1.7 million years ago; however, the earliest solid evidence for the existence of home bases or central campsites (hearths and shelters) among humans only dates back to 500,000 years ago. Similarly, scientists disagree whether Lower Paleolithic humans were largely monogamous or polygynous. In particular, the Provisional model suggests that bipedalism arose in pre-Paleolithic australopithecine societies as an adaptation to monogamous lifestyles; however, other researchers note that sexual dimorphism is more pronounced in Lower Paleolithic humans such as Homo erectus than in modern humans, who are less polygynous than other primates, which suggests that Lower Paleolithic humans had a largely polygynous lifestyle, because species that have the most pronounced sexual dimorphism tend more likely to be polygynous. Human societies from the Paleolithic to the early Neolithic farming tribes lived without states and organized governments.
Despite this, modern technology is increasingly reliant on deep, domain-specific scientific knowledge. In 1975, there was an average of one citation of scientific literature in every three patents granted in the U.S.; by 1989, this increased to an average of one citation per patent. The average was skewed upwards by patents related to the pharmaceutical industry, chemistry, and electronics. A 2021 analysis shows that patents that are based on scientific discoveries are on average 26% more valuable than equivalent non-science-based patents.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.